Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Press Release: Pfizer and BioNTech to Provide 500 -3-

06/10/2021 | 02:00am EDT
periods as previously indicated; whether and when additional supply 
agreements will be reached; uncertainties regarding the ability to 
obtain recommendations from vaccine advisory or technical committees and 
other public health authorities and uncertainties regarding the 
commercial impact of any such recommendations; challenges related to 
public vaccine confidence or awareness; uncertainties regarding the 
impact of COVID-19 on Pfizer's business, operations and financial 
results; and competitive developments. 
   A further description of risks and uncertainties can be found in 
Pfizer's Annual Report on Form 10-K for the fiscal year ended December 
31, 2020 and in its subsequent reports on Form 10-Q, including in the 
sections thereof captioned "Risk Factors" and "Forward-Looking 
Information and Factors That May Affect Future Results", as well as in 
its subsequent reports on Form 8-K, all of which are filed with the U.S. 
Securities and Exchange Commission and available at 
www.sec.gov and 
   About BioNTech 
   Biopharmaceutical New Technologies is a next generation immunotherapy 
company pioneering novel therapies for cancer and other serious 
diseases. The Company exploits a wide array of computational discovery 
and therapeutic drug platforms for the rapid development of novel 
biopharmaceuticals. Its broad portfolio of oncology product candidates 
includes individualized and off-the-shelf mRNA-based therapies, 
innovative chimeric antigen receptor T cells, bi-specific checkpoint 
immuno-modulators, targeted cancer antibodies and small molecules. Based 
on its deep expertise in mRNA vaccine development and in-house 
manufacturing capabilities, BioNTech and its collaborators are 
developing multiple mRNA vaccine candidates for a range of infectious 
diseases alongside its diverse oncology pipeline. BioNTech has 
established a broad set of relationships with multiple global 
pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal 
Health, Genentech, a member of the Roche Group, Regeneron, Genevant, 
Fosun Pharma, and Pfizer. For more information, please visit 
   BioNTech Forward-looking Statements 
   This press release contains "forward-looking statements" of BioNTech 
within the meaning of the Private Securities Litigation Reform Act of 
1995. These forward-looking statements may include, but may not be 
limited to, statements concerning: BioNTech's efforts to combat 
COVID-19; the collaboration between BioNTech and Pfizer to develop a 
COVID-19 vaccine (including a potential second booster dose of BNT162b2 
and/or a potential booster dose of a variation of BNT162b2 having a 
modified mRNA sequence); our expectations regarding the potential 
characteristics of BNT162b2 in our clinical trials and/or in commercial 
use based on data observations to date; the ability of BNT162b2 to 
prevent COVID-19 caused by emerging virus variants; the expected time 
point for additional readouts on efficacy data of BNT162b2 in our 
clinical trials; the nature of the clinical data, which is subject to 
ongoing peer review, regulatory review and market interpretation; the 
timing for submission of data for, or receipt of, any marketing approval 
or Emergency Use Authorization; our contemplated shipping and storage 
plan, including our estimated product shelf life at various 
temperatures; and the ability of BioNTech to supply the quantities of 
BNT162 to support clinical development and market demand, including our 
production estimates for 2021. Any forward-looking statements in this 
press release are based on BioNTech current expectations and beliefs of 
future events, and are subject to a number of risks and uncertainties 
that could cause actual results to differ materially and adversely from 
those set forth in or implied by such forward-looking statements. These 
risks and uncertainties include, but are not limited to: the ability to 
meet the pre-defined endpoints in clinical trials; competition to create 
a vaccine for COVID-19; the ability to produce comparable clinical or 
other results, including our stated rate of vaccine effectiveness and 
safety and tolerability profile observed to date, in the remainder of 
the trial or in larger, more diverse populations upon commercialization; 
the ability to effectively scale our productions capabilities; and other 
potential difficulties. 
   For a discussion of these and other risks and uncertainties, see 
BioNTech's Annual Report as Form 20-F for the Year Ended December 31, 
2020, filed with the SEC on March 30, 2021, which is available on the 
SEC's website at www.sec.gov. All information in this press release is 
as of the date of the release, and BioNTech undertakes no duty to update 
this information unless required by law. 
   Pfizer Contacts: 
   Media Relations 
   Amy Rose 
   +1 (212) 733-7410 
   Investor Relations 
   Chuck Triano 
   +1 (212) 733-3901 
   BioNTech Contacts: 
   Media Relations 
   Jasmina Alatovic 
   +49 (0)6131 9084 1513 
   Investor Relations 
   Sylke Maas, Ph.D. 
   +49 (0)6131 9084 1074 

(END) Dow Jones Newswires

June 10, 2021 02:00 ET (06:00 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
BAYER AG -1.46% 50.55 Delayed Quote.6.53%
BIONTECH SE -2.96% 229.5 Delayed Quote.190.10%
DJ INDUSTRIAL -0.21% 33874.24 Delayed Quote.10.91%
GENMAB A/S -3.08% 2615 Delayed Quote.9.54%
PFIZER, INC. -1.41% 39.05 Delayed Quote.7.61%
SANOFI -0.70% 87.12 Real-time Quote.11.47%
All news about BIONTECH SE
03:12pMODERNAá : NIH begins clinical trial testing COVID-19 vaccine in pregnant women
11:56aEuropean ADRs Edge Higher in Wednesday Trading
11:49aUS' CDC To Study Possible Link Between Heart Inflammation And Pfizer/BioNTech..
10:17aBIONTECHá : EMA - Two additional manufacturing sites for BioNTech Pfizer's COVID..
10:16aGLOBAL MARKETS LIVE : Microsoft, Morgan Stanley, Heineken, Twitter, AstraZeneca...
10:03aSIEMENSá : To Provide Technology Support For BioNTech's Vaccine Production Sites
09:08aToday on Wall Street: We shall not be ruled by inflation fears
08:20aSiemens, BioNTech to Expand Vaccine Production Collaboration
02:11aDebate Intensifies Over A Vaccine IP Waiver's Impact On Future Pharma And Bio..
01:02aSECTORAL ASSET MANAGEMENTá : Covid-Vaccine Patent Waiver: Will it Increase World..
More news
Sales 2021 12 387 M 14 772 M 14 772 M
Net income 2021 7 065 M 8 425 M 8 425 M
Net cash 2021 7 669 M 9 145 M 9 145 M
P/E ratio 2021 7,00x
Yield 2021 -
Capitalization 47 849 M 57 117 M 57 060 M
EV / Sales 2021 3,24x
EV / Sales 2022 3,23x
Nbr of Employees 2 200
Free-Float 87,3%
Duration : Period :
BioNTech SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 13
Last Close Price 198,12 €
Average target price 148,37 €
Spread / Average Target -25,1%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Sierk P÷tting Chief Operating & Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Ízlem TŘreci Chief Medical Officer
Christoph Huber Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BIONTECH SE190.10%57 117
WUXI APPTEC CO., LTD.36.51%68 536
BEIGENE, LTD.28.69%30 775